| 8.23 Data as of May 22 |  -0.38 / -4.41%Today’s Change | 3.72 Today|||52-Week Range 9.65 | +31.05% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $270.7M |
Company Description
Repligen Corp. is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Repligen's bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. The company is a manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. Repligen also supplies several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, Repligen has developed and markets a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. In addition to its core bioprocessing business, Repligen has a portfolio of clinical-stage partnering assets, including two central nervous system orphan drug candidates and a pancreatic imaging agent in Phase 3 development. Repligen has a manufacturing facility in Lund, Sweden. It was founded by Alexander Rich in May 1981 and is headquartered in Waltham, MA.
Employees
Shareholders
| Other institutional | 32.35% |
| Mutual fund holders | 22.48% |
| Individual stakeholders | 16.77% |
Top Executives
| Walter C. Herlihy, PhD | President, Chief Executive Officer & Director |
| Daniel P. Witt, PhD | Senior Vice President-Global Operations |
| Jonathan I. Lieber, MBA | Chief Financial Officer & Treasurer |
| Michael L. Hall, MD | Chief Medical Officer & SVP-Regulatory Affairs |
| James R. Rusche, PhD | Senior Vice President-Research & Development |
.
